首页 > 最新文献

Future Virology最新文献

英文 中文
A plain language summary of the Janssen COVID-19 vaccine effectiveness and safety as a single dose and with a booster 杨森COVID-19疫苗单剂和加强剂的有效性和安全性的简明语言总结
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-09-14 DOI: 10.2217/fvl-2022-0105
F. Struyf, J. Sadoff, K. Hardt, M. Douoguih
Summary This is a summary of the results of 2 global clinical studies of the Janssen Ad26.COV2.S vaccine against COVID-19. The ENSEMBLE study looked at the effectiveness of a single injection of the vaccine. The separate ENSEMBLE2 study looked at the effectiveness of a booster dose of the vaccine given 2 months after the first dose. In both studies, people received either the vaccine or a placebo. Vaccine effectiveness was evaluated 14 and 28 days after vaccination to allow sufficient time for generation of an immune response. In ENSEMBLE, compared to the placebo, a single dose of the vaccine prevented: 56% of moderate to severe-critical COVID-19 cases occurring at least 14 days after vaccination 53% of moderate to severe-critical COVID-19 cases occurring at least 28 days after vaccination 75% of severe-critical COVID-19 cases occurring at least 28 days after vaccination 76% of people with COVID-19 from needing to be hospitalized for treatment 83% of COVID-19–related deaths The vaccine continued to work well for at least 6 months after a single vaccine injection. In ENSEMBLE2, compared to the placebo, a single dose of the vaccine followed by a booster dose 2 months later prevented: 75% of moderate to severe-critical COVID-19 cases occurring at least 14 days after booster vaccination 100% of severe-critical COVID-19 cases occurring at least 14 days after booster vaccination In ENSEMBLE2, there were too few cases of COVID-19 to estimate vaccine effectiveness for preventing COVID-19–related deaths or hospitalization. ENSEMBLE2 was done during early 2021, when several COVID-19 vaccines became available by emergency use authorization. For ethical reasons, people could check whether they had received vaccine or placebo and decide whether they could be vaccinated outside of the study. This meant that the researchers could not look at the long-term effectiveness of the vaccine. In both studies, after receiving the vaccine, some people experienced pain at the injection site, headache, tiredness, muscle pain, and nausea. In most cases, these were mild and went away within a few days. Serious side effects were very rare. In ENSEMBLE, blood clots, seizures, hives, and ringing in the ears were more common in the people who got the vaccine than in those who got the placebo. These side effects were very rare. In ENSEMBLE2, bleeding, hives, and ringing in the ears were slightly more common in people who got the vaccine than those who got the placebo. In ENSEMBLE2, blood clots were more common in people who got the placebo. At the time of the study, it was not clear if these side effects were caused by the vaccine. The vaccine was effective at protecting against moderate to severe-critical COVID-19 at 14 days after a single injection. Effectiveness was increased by a booster injection given 2 months after the first injection. You can find more detailed information and references in the original articles. Links to these articles can be found at the end of this sum
摘要这是针对新冠肺炎杨森Ad26.COV2.S疫苗的2项全球临床研究结果的摘要。ENSEMBLE的研究着眼于单次注射疫苗的有效性。ENSEMBLE2的另一项研究考察了第一剂疫苗接种后2个月接种加强剂疫苗的有效性。在这两项研究中,人们要么接种了疫苗,要么服用了安慰剂。在接种疫苗后14天和28天评估疫苗有效性,以便有足够的时间产生免疫反应。ENSEMBLE与安慰剂相比,单剂疫苗预防:56%的中重度新冠肺炎病例在接种疫苗后至少14天发生53%的中重度新冠肺炎病例在接种后至少28天发生75%的重度新冠肺炎病例在接种了疫苗后至少28天后发生76%的新冠肺炎患者无需住院治疗83%的新冠肺炎相关死亡单次注射疫苗后,疫苗至少在6个月内继续有效。在ENSEMBLE2中,与安慰剂相比,单剂疫苗2个月后接种加强剂预防了75%的中重度新冠肺炎病例在加强针接种后至少14天发生100%的重度新冠肺炎病例在加强疫苗接种后至少十四天发生,新冠肺炎病例太少,无法估计疫苗预防新冠肺炎相关死亡或住院的有效性。ENSEMBLE2是在2021年初完成的,当时几种新冠肺炎疫苗已获得紧急使用授权。出于伦理原因,人们可以检查自己是否接种了疫苗或安慰剂,并决定是否可以在研究之外接种疫苗。这意味着研究人员无法观察疫苗的长期有效性。在这两项研究中,接种疫苗后,一些人出现注射部位疼痛、头痛、疲劳、肌肉疼痛和恶心。在大多数情况下,这些症状都很轻微,并在几天内消失。严重的副作用非常罕见。在ENSEMBLE,接种疫苗的人比接种安慰剂的人更常见血栓、癫痫发作、荨麻疹和耳鸣。这些副作用非常罕见。在ENSEMBLE2中,接种疫苗的人比接种安慰剂的人更常见出血、荨麻疹和耳鸣。在ENSEMBLE2中,血栓在服用安慰剂的人中更常见。在进行研究时,尚不清楚这些副作用是否是由疫苗引起的。单次注射后14天,该疫苗在预防中重度新冠肺炎方面有效。在第一次注射后2个月进行加强针注射可提高疗效。您可以在原始文章中找到更详细的信息和参考资料。这些文章的链接可以在本摘要的末尾找到。临床试验注册:NCT04505722和NCT04614948(ClinicalTrials.gov)
{"title":"A plain language summary of the Janssen COVID-19 vaccine effectiveness and safety as a single dose and with a booster","authors":"F. Struyf, J. Sadoff, K. Hardt, M. Douoguih","doi":"10.2217/fvl-2022-0105","DOIUrl":"https://doi.org/10.2217/fvl-2022-0105","url":null,"abstract":"Summary This is a summary of the results of 2 global clinical studies of the Janssen Ad26.COV2.S vaccine against COVID-19. The ENSEMBLE study looked at the effectiveness of a single injection of the vaccine. The separate ENSEMBLE2 study looked at the effectiveness of a booster dose of the vaccine given 2 months after the first dose. In both studies, people received either the vaccine or a placebo. Vaccine effectiveness was evaluated 14 and 28 days after vaccination to allow sufficient time for generation of an immune response. In ENSEMBLE, compared to the placebo, a single dose of the vaccine prevented: 56% of moderate to severe-critical COVID-19 cases occurring at least 14 days after vaccination 53% of moderate to severe-critical COVID-19 cases occurring at least 28 days after vaccination 75% of severe-critical COVID-19 cases occurring at least 28 days after vaccination 76% of people with COVID-19 from needing to be hospitalized for treatment 83% of COVID-19–related deaths The vaccine continued to work well for at least 6 months after a single vaccine injection. In ENSEMBLE2, compared to the placebo, a single dose of the vaccine followed by a booster dose 2 months later prevented: 75% of moderate to severe-critical COVID-19 cases occurring at least 14 days after booster vaccination 100% of severe-critical COVID-19 cases occurring at least 14 days after booster vaccination In ENSEMBLE2, there were too few cases of COVID-19 to estimate vaccine effectiveness for preventing COVID-19–related deaths or hospitalization. ENSEMBLE2 was done during early 2021, when several COVID-19 vaccines became available by emergency use authorization. For ethical reasons, people could check whether they had received vaccine or placebo and decide whether they could be vaccinated outside of the study. This meant that the researchers could not look at the long-term effectiveness of the vaccine. In both studies, after receiving the vaccine, some people experienced pain at the injection site, headache, tiredness, muscle pain, and nausea. In most cases, these were mild and went away within a few days. Serious side effects were very rare. In ENSEMBLE, blood clots, seizures, hives, and ringing in the ears were more common in the people who got the vaccine than in those who got the placebo. These side effects were very rare. In ENSEMBLE2, bleeding, hives, and ringing in the ears were slightly more common in people who got the vaccine than those who got the placebo. In ENSEMBLE2, blood clots were more common in people who got the placebo. At the time of the study, it was not clear if these side effects were caused by the vaccine. The vaccine was effective at protecting against moderate to severe-critical COVID-19 at 14 days after a single injection. Effectiveness was increased by a booster injection given 2 months after the first injection. You can find more detailed information and references in the original articles. Links to these articles can be found at the end of this sum","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42304045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sudden onset of decreased vision following Delta variant of SARS-CoV-2 infection: a case report δ型SARS-CoV-2感染后突然出现视力下降1例报告
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-08-31 DOI: 10.2217/fvl-2022-0006
A. Ahmadi, N. Shafiei-Jandaghi, K. Sadeghi, M. Salehi, T. Mokhtari-azad, J. Yavarian
We described a 52-year-old male patient with COVID-19 who had sudden decreased vision in his left eye in the second week of his illness. No occlusion thrombotic vein or hemorrhagic spots in retina have been identified in ophthalmoscopy procedures, clinical examination and optical coherence tomography. In one month his vision became normal without any treatment. We could not find the exact mechanisms of one-sided decreased vision in the COVID-19 patient, but this problem should be considered by physicians because of the importance of loss of vision.
我们描述了一名52岁的新冠肺炎男性患者,他在患病的第二周左眼视力突然下降。在检眼镜检查、临床检查和光学相干断层扫描中,没有发现视网膜中的闭塞性血栓性静脉或出血点。一个月后,他的视力在没有任何治疗的情况下恢复正常。我们无法找到新冠肺炎患者单侧视力下降的确切机制,但由于视力下降的重要性,医生应该考虑这个问题。
{"title":"Sudden onset of decreased vision following Delta variant of SARS-CoV-2 infection: a case report","authors":"A. Ahmadi, N. Shafiei-Jandaghi, K. Sadeghi, M. Salehi, T. Mokhtari-azad, J. Yavarian","doi":"10.2217/fvl-2022-0006","DOIUrl":"https://doi.org/10.2217/fvl-2022-0006","url":null,"abstract":"We described a 52-year-old male patient with COVID-19 who had sudden decreased vision in his left eye in the second week of his illness. No occlusion thrombotic vein or hemorrhagic spots in retina have been identified in ophthalmoscopy procedures, clinical examination and optical coherence tomography. In one month his vision became normal without any treatment. We could not find the exact mechanisms of one-sided decreased vision in the COVID-19 patient, but this problem should be considered by physicians because of the importance of loss of vision.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47353285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A case report of dengue shock syndrome complicated with multiorgan failure and hepatitis E virus superinfection 登革热休克综合征并发多器官功能衰竭和戊型肝炎病毒重叠感染1例报告
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-08-25 DOI: 10.2217/fvl-2021-0239
Kinza Waqar, Hashaam Akhtar, Muhammad Mujeeb Khan, M. Umar, B. Malik, M. Faheem
Dengue fever is a vector borne viral disease. It is more prevalent in Southeast Asia. The main symptoms include myalgia, nausea, vomiting and rash, hence, subsequently lead to dengue hemorrhagic fever and dengue shock syndrome. In the current report, we are presenting a case of a 50-year-old female patient who was presented in hospital with the symptoms of fever, vomiting, abdominal pain, productive cough and sore throat. Her serology came positive for dengue NSP1, and she was shifted to intensive care unit because of her aggravating condition. On day 4, the hepatitis E virus infection also was detected and she died after developing hepatic shock and multiorgan failure. This report states the superinfection of hepatitis E and dengue virus and highlights the significance of its early detection for better clinical management.
登革热是一种病媒传播的病毒性疾病。它在东南亚更为普遍。主要症状包括肌痛、恶心、呕吐和皮疹,因此可导致登革出血热和登革休克综合征。在本报告中,我们报告了一例50岁女性患者,她以发烧、呕吐、腹痛、咳嗽和喉咙痛等症状住院。她的登革热NSP1血清学呈阳性,由于病情加重,她被转移到重症监护病房。第4天检测出戊型肝炎病毒感染,并发肝休克和多器官衰竭死亡。本报告阐述了戊型肝炎和登革热病毒的重复感染,并强调了早期发现对更好的临床管理的重要性。
{"title":"A case report of dengue shock syndrome complicated with multiorgan failure and hepatitis E virus superinfection","authors":"Kinza Waqar, Hashaam Akhtar, Muhammad Mujeeb Khan, M. Umar, B. Malik, M. Faheem","doi":"10.2217/fvl-2021-0239","DOIUrl":"https://doi.org/10.2217/fvl-2021-0239","url":null,"abstract":"Dengue fever is a vector borne viral disease. It is more prevalent in Southeast Asia. The main symptoms include myalgia, nausea, vomiting and rash, hence, subsequently lead to dengue hemorrhagic fever and dengue shock syndrome. In the current report, we are presenting a case of a 50-year-old female patient who was presented in hospital with the symptoms of fever, vomiting, abdominal pain, productive cough and sore throat. Her serology came positive for dengue NSP1, and she was shifted to intensive care unit because of her aggravating condition. On day 4, the hepatitis E virus infection also was detected and she died after developing hepatic shock and multiorgan failure. This report states the superinfection of hepatitis E and dengue virus and highlights the significance of its early detection for better clinical management.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45891620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of virologic outcome in low-level HIV-1 viremia patients in a small cohort 一个小队列低水平HIV-1病毒血症患者的病毒学结果分析
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-07-27 DOI: 10.2217/fvl-2021-0195
Lisha Ding, Xi Chen, Jian-mei He, Jun Zheng, Xiuqing Wei, Bi-yun Qin, Xiangzhong Li
Aim: It is unclear whether a low-level viremia (LLV) status is maintained in HIV-infected patients. Materials & methods: HIV-infected patients with LLV were enrolled and followed up for 5 years. Factors associated with virological outcomes were assessed via regression analyses. Results: A total of 39 patients maintained an LLV status, whereas 19 had disease progression with a viral load of ≥1000 copies/ml. LLV duration and drug resistance (DR) were associated with virological failure. Among the DR cases, the most frequent mutations were M184V/I (70.4%) and K103N (40.7%). Protease inhibitor (PI) mutations were rare. Conclusion: There is an increased risk for virologic failure in HIV-1-infected patients maintaining LLV for a long time. DR was not a rare phenomenon in LLV patients.
目的:目前尚不清楚hiv感染患者是否维持低水平病毒血症(LLV)状态。材料与方法:纳入hiv感染的LLV患者,随访5年。通过回归分析评估与病毒学结果相关的因素。结果:共有39例患者维持LLV状态,而19例患者出现病毒载量≥1000拷贝/ml的疾病进展。LLV持续时间和耐药性(DR)与病毒学失败相关。DR病例中最常见的突变是M184V/I(70.4%)和K103N(40.7%)。蛋白酶抑制剂(PI)突变是罕见的。结论:长期维持LLV的hiv -1感染患者发生病毒学失败的风险增加。DR在LLV患者中并不罕见。
{"title":"Analysis of virologic outcome in low-level HIV-1 viremia patients in a small cohort","authors":"Lisha Ding, Xi Chen, Jian-mei He, Jun Zheng, Xiuqing Wei, Bi-yun Qin, Xiangzhong Li","doi":"10.2217/fvl-2021-0195","DOIUrl":"https://doi.org/10.2217/fvl-2021-0195","url":null,"abstract":"Aim: It is unclear whether a low-level viremia (LLV) status is maintained in HIV-infected patients. Materials & methods: HIV-infected patients with LLV were enrolled and followed up for 5 years. Factors associated with virological outcomes were assessed via regression analyses. Results: A total of 39 patients maintained an LLV status, whereas 19 had disease progression with a viral load of ≥1000 copies/ml. LLV duration and drug resistance (DR) were associated with virological failure. Among the DR cases, the most frequent mutations were M184V/I (70.4%) and K103N (40.7%). Protease inhibitor (PI) mutations were rare. Conclusion: There is an increased risk for virologic failure in HIV-1-infected patients maintaining LLV for a long time. DR was not a rare phenomenon in LLV patients.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47421235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV infection and the risk of cancer: tumorigenicity of HIV-1 auxiliary proteins HIV感染与癌症风险:HIV-1辅助蛋白的致瘤性
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-07-19 DOI: 10.2217/fvl-2022-0065
S. Mowla, Riyaadh Ahmed
{"title":"HIV infection and the risk of cancer: tumorigenicity of HIV-1 auxiliary proteins","authors":"S. Mowla, Riyaadh Ahmed","doi":"10.2217/fvl-2022-0065","DOIUrl":"https://doi.org/10.2217/fvl-2022-0065","url":null,"abstract":"","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47661868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prevalence of occult hepatitis B infection in liver biopsy sample of patients with nonviral liver disease 非病毒性肝病患者肝活检样本中隐性乙型肝炎感染的患病率
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-07-19 DOI: 10.2217/fvl-2021-0316
B. Cakal, A. Atasoy, B. Çavuş, M. Poda, M. Bulakci, M. Gulluoglu, M. Demirci, F. Akyuz
Aim: To determine the prevalence of occult hepatitis B (HBV) infection (OBI) in patients with nonviral liver disease. Materials & methods: This study included 83 HBsAg-negative patients followed up at a gastroenterohepatology clinic. The presence of HBV DNA was investigated by using an in-house nested-PCR method applied to liver parenchymal biopsy samples obtained from patients who underwent due nonviral chronic liver disease. Results: OBI was detected in 19 (22.9%) of the 83 cases, in 11 (44%) of 25 anti-HBc-positive patients, and 15 (31.9%) of 47 anti-HBc and/or anti-HBs antibodies-positive patients. Conclusion: There is a considerable prevalence of OBI among patients with nonviral chronic liver disease. Therefore, it is suggested that closely monitoring HBV can be useful to prevent or more effectively manage possible OBI-related complications among patients with nonviral chronic liver disease, especially those who are HBsAg seronegative or anti-HBV antibody seropositive.
目的:确定非病毒性肝病患者隐性乙型肝炎(HBV)感染(OBI)的患病率。材料与方法:本研究包括83名在胃肠道肝炎诊所随访的HBsAg阴性患者。通过使用内部嵌套PCR方法对HBV DNA的存在进行调查,该方法应用于从接受非病毒性慢性肝病的患者获得的肝实质活检样本。结果:83例患者中有19例(22.9%)、25例抗-HBc阳性患者中有11例(44%)、47例抗-HBc和/或抗-HBs抗体阳性患者中15例(31.9%)检测到OBI。结论:OBI在非病毒性慢性肝病患者中有相当大的患病率。因此,密切监测HBV有助于预防或更有效地管理非病毒性慢性肝病患者,特别是HBsAg血清阴性或抗HBV抗体血清阳性患者可能出现的OBI相关并发症。
{"title":"Prevalence of occult hepatitis B infection in liver biopsy sample of patients with nonviral liver disease","authors":"B. Cakal, A. Atasoy, B. Çavuş, M. Poda, M. Bulakci, M. Gulluoglu, M. Demirci, F. Akyuz","doi":"10.2217/fvl-2021-0316","DOIUrl":"https://doi.org/10.2217/fvl-2021-0316","url":null,"abstract":"Aim: To determine the prevalence of occult hepatitis B (HBV) infection (OBI) in patients with nonviral liver disease. Materials & methods: This study included 83 HBsAg-negative patients followed up at a gastroenterohepatology clinic. The presence of HBV DNA was investigated by using an in-house nested-PCR method applied to liver parenchymal biopsy samples obtained from patients who underwent due nonviral chronic liver disease. Results: OBI was detected in 19 (22.9%) of the 83 cases, in 11 (44%) of 25 anti-HBc-positive patients, and 15 (31.9%) of 47 anti-HBc and/or anti-HBs antibodies-positive patients. Conclusion: There is a considerable prevalence of OBI among patients with nonviral chronic liver disease. Therefore, it is suggested that closely monitoring HBV can be useful to prevent or more effectively manage possible OBI-related complications among patients with nonviral chronic liver disease, especially those who are HBsAg seronegative or anti-HBV antibody seropositive.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46577480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunomodulatory effects of probiotic Lactobacillus casei on GM-CSF-adjuvanted influenza DNA vaccine 益生菌干酪乳杆菌对gm - csf佐剂流感DNA疫苗的免疫调节作用
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-07-15 DOI: 10.2217/fvl-2021-0327
Mehran Mahooti, Elahe Abdolalipour, B. Farahmand, S. Shirian, A. Ghaemi
Aim: This study investigates the protective efficacy of influenza DNA vaccine combined with a granulocyte macrophage-colony stimulating factor (GM-CSF) adjuvant, and probiotic Lactobacillus casei, an oral immunomodulator, in a BALB/c mice. Materials & methods: The mice were immunized with HA1 DNA vaccine along with GM-CSF and probiotic twice within a one-week interval. Results: The results showed that both adjuvants exert a synergistic effect in enhancing the humoral and cellular immune responses of the DNA vaccine. This combination also deceased IL-6 and IL-17A levels in the lung homogenates. The protection patterns were closely associated with influenza virus-specific splenocyte proliferative and serum IgG antibody (Ab) responses. Conclusion: The Findings demonstrate L. casei modulate balanced Th1/Th2 immune responses toward HA1 DNA vaccine adjuvanted by GM-CSF.
目的:研究流感DNA疫苗联合粒细胞-巨噬细胞集落刺激因子(GM-CSF)佐剂和益生菌干酪乳杆菌(口服免疫调节剂)对BALB/c小鼠的保护作用。材料与方法:用HA1DNA疫苗、GM-CSF和益生菌在一周内免疫小鼠两次。结果:两种佐剂在增强DNA疫苗的体液和细胞免疫反应方面具有协同作用。这种组合还降低了肺匀浆中IL-6和IL-17A的水平。保护模式与流感病毒特异性脾细胞增殖和血清IgG抗体(Ab)反应密切相关。结论:干酪乳杆菌对经GM-CSF佐剂的HA1DNA疫苗调节平衡的Th1/Th2免疫应答。
{"title":"Immunomodulatory effects of probiotic Lactobacillus casei on GM-CSF-adjuvanted influenza DNA vaccine","authors":"Mehran Mahooti, Elahe Abdolalipour, B. Farahmand, S. Shirian, A. Ghaemi","doi":"10.2217/fvl-2021-0327","DOIUrl":"https://doi.org/10.2217/fvl-2021-0327","url":null,"abstract":"Aim: This study investigates the protective efficacy of influenza DNA vaccine combined with a granulocyte macrophage-colony stimulating factor (GM-CSF) adjuvant, and probiotic Lactobacillus casei, an oral immunomodulator, in a BALB/c mice. Materials & methods: The mice were immunized with HA1 DNA vaccine along with GM-CSF and probiotic twice within a one-week interval. Results: The results showed that both adjuvants exert a synergistic effect in enhancing the humoral and cellular immune responses of the DNA vaccine. This combination also deceased IL-6 and IL-17A levels in the lung homogenates. The protection patterns were closely associated with influenza virus-specific splenocyte proliferative and serum IgG antibody (Ab) responses. Conclusion: The Findings demonstrate L. casei modulate balanced Th1/Th2 immune responses toward HA1 DNA vaccine adjuvanted by GM-CSF.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49088916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sequence analysis of Epstein–Barr virus BALF2 gene in associated tumors and healthy individuals from southern and northern China 中国南方和北方地区相关肿瘤及健康人群爱泼斯坦-巴尔病毒BALF2基因序列分析
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-07-07 DOI: 10.2217/fvl-2021-0177
Cai-xia Yu, Wen Liu, Meng-he Zhao, Hua Xiao, Yun Wang, B. Luo
Aim: The purpose of this study is to investigate the polymorphism and distribution characteristics of BALF2 gene in Epstein–Barr virus (EBV)-associated tumors (gastric cancer, nasopharyngeal carcinoma and lymphoma). Materials & methods: DNA sequences of 349 EBV-related samples were analyzed by nested PCR combined with DNA sequencing. Results: According to the phylogenetic tree, BALF2 was divided into six genotypes ( BALF2-A–F). Statistically, the incidence of BALF2-E in nasopharyngeal carcinoma was higher than that in healthy people, and the incidence of BALF2-E in nasopharyngeal carcinoma in South China was higher than that in North China (p = 0.001). Conclusion: BALF2 variants in EBV-associated samples are not only tumor-specific, but also differ between northern and southern regions.
目的:探讨eb病毒(EBV)相关肿瘤(胃癌、鼻咽癌和淋巴瘤)中BALF2基因多态性及其分布特征。材料与方法:采用巢式PCR结合DNA测序法对349份ebv相关样本进行DNA序列分析。结果:根据系统发育树,BALF2被划分为6个基因型(BALF2- a - f)。统计学上,BALF2-E在鼻咽癌中的发病率高于健康人,华南鼻咽癌BALF2-E的发病率高于华北地区(p = 0.001)。结论:ebv相关样本中的BALF2变异不仅具有肿瘤特异性,而且在南北地区存在差异。
{"title":"Sequence analysis of Epstein–Barr virus BALF2 gene in associated tumors and healthy individuals from southern and northern China","authors":"Cai-xia Yu, Wen Liu, Meng-he Zhao, Hua Xiao, Yun Wang, B. Luo","doi":"10.2217/fvl-2021-0177","DOIUrl":"https://doi.org/10.2217/fvl-2021-0177","url":null,"abstract":"Aim: The purpose of this study is to investigate the polymorphism and distribution characteristics of BALF2 gene in Epstein–Barr virus (EBV)-associated tumors (gastric cancer, nasopharyngeal carcinoma and lymphoma). Materials & methods: DNA sequences of 349 EBV-related samples were analyzed by nested PCR combined with DNA sequencing. Results: According to the phylogenetic tree, BALF2 was divided into six genotypes ( BALF2-A–F). Statistically, the incidence of BALF2-E in nasopharyngeal carcinoma was higher than that in healthy people, and the incidence of BALF2-E in nasopharyngeal carcinoma in South China was higher than that in North China (p = 0.001). Conclusion: BALF2 variants in EBV-associated samples are not only tumor-specific, but also differ between northern and southern regions.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46085013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis. 治疗 COVID-19 住院患者的皮质类固醇方案的有效性和安全性:一项荟萃分析。
IF 2.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-07-01 Epub Date: 2022-06-03 DOI: 10.2217/fvl-2021-0244
Fangwen Zhou, Jiawen Deng, Kiyan Heybati, Qi Kang Zuo, Saif Ali, Wenteng Hou, Chi Yi Wong, Harikrishnaa Ba Ramaraju, Oswin Chang, Thanansayan Dhivagaran, Zachary Silver

Aim: To evaluate the efficacy and safety of corticosteroids for treating hospitalized COVID-19 patients.

Materials & methods: Efficacy outcomes included time to negative SARS-CoV-2 tests, length of stay, duration and incidence of intensive unit care stay, incidence of mortality and duration and incidence of mechanical ventilation. Safety outcomes included the incidence of adverse events and severe adverse events, incidence of hyperglycemia and incidence of nosocomial infections.

Results: Ninety-five randomized controlled trials (RCTs) and observational studies (n = 42,205) were included. Corticosteroids were associated with increased length of stay (based on RCT only), increased time to negative tests, decreased length of mechanical ventilation and increased odds of hyperglycemia.

Conclusion: Corticosteroids should be considered in patients requiring mechanical ventilation, and glycemic monitoring may be needed when administering corticosteroids.

目的:评估皮质类固醇治疗 COVID-19 住院患者的疗效和安全性:疗效指标包括SARS-CoV-2检测阴性时间、住院时间、重症监护室住院时间和发生率、死亡率、机械通气时间和发生率。安全性结果包括不良事件和严重不良事件的发生率、高血糖的发生率以及院内感染的发生率:结果:共纳入 95 项随机对照试验 (RCT) 和观察性研究(n = 42 205)。皮质类固醇与住院时间延长(仅基于随机对照试验)、检测阴性时间延长、机械通气时间缩短和高血糖几率增加有关:结论:需要机械通气的患者应考虑使用皮质类固醇,在使用皮质类固醇时可能需要进行血糖监测。
{"title":"Efficacy and safety of corticosteroid regimens for the treatment of hospitalized COVID-19 patients: a meta-analysis.","authors":"Fangwen Zhou, Jiawen Deng, Kiyan Heybati, Qi Kang Zuo, Saif Ali, Wenteng Hou, Chi Yi Wong, Harikrishnaa Ba Ramaraju, Oswin Chang, Thanansayan Dhivagaran, Zachary Silver","doi":"10.2217/fvl-2021-0244","DOIUrl":"10.2217/fvl-2021-0244","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy and safety of corticosteroids for treating hospitalized COVID-19 patients.</p><p><strong>Materials & methods: </strong>Efficacy outcomes included time to negative SARS-CoV-2 tests, length of stay, duration and incidence of intensive unit care stay, incidence of mortality and duration and incidence of mechanical ventilation. Safety outcomes included the incidence of adverse events and severe adverse events, incidence of hyperglycemia and incidence of nosocomial infections.</p><p><strong>Results: </strong>Ninety-five randomized controlled trials (RCTs) and observational studies (n = 42,205) were included. Corticosteroids were associated with increased length of stay (based on RCT only), increased time to negative tests, decreased length of mechanical ventilation and increased odds of hyperglycemia.</p><p><strong>Conclusion: </strong>Corticosteroids should be considered in patients requiring mechanical ventilation, and glycemic monitoring may be needed when administering corticosteroids.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":"17 7","pages":"463-489"},"PeriodicalIF":2.1,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249165/pdf/fvl-17-463.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10309232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SARS-CoV-2 and its repercussive effect on reproductive health: recent trends SARS-CoV-2及其对生殖健康的影响:近期趋势
IF 3.1 4区 医学 Q3 VIROLOGY Pub Date : 2022-07-01 DOI: 10.2217/fvl-2021-0315
Sukanth Kumar Enmozhi, Jerrine Joseph
{"title":"SARS-CoV-2 and its repercussive effect on reproductive health: recent trends","authors":"Sukanth Kumar Enmozhi, Jerrine Joseph","doi":"10.2217/fvl-2021-0315","DOIUrl":"https://doi.org/10.2217/fvl-2021-0315","url":null,"abstract":"","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45403336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Future Virology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1